Abzena plc (ABZA LN)

Analysis

Health Care • United Kingdom

Abzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. The company?s services and technologies address critical research and development issues to enable the development of better biopharmaceutical products. It offers iTope, TCED, and EpiScreen technologies for the assessment of the potential immunogenicity of a biopharmaceutical product; and ThioBridge technology to produce more stable and homogeneous antibody drug conjugates. The company also provides Composite Human Antibodies and Composite Proteins for the immunogenic therapeutic antibodies and proteins; TheraPEG, HiPEG, CyPEG, and PolyPEG for the optimization of the pharmacokinetics and pharmacodynamics of protein therapeutics; and Composite CHO for the development of cell lines for the manufacture of therapeutic antibodies. It serves biopharmaceutical research and development industry. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00